Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Non-Current Assets (2016 - 2025)

UroGen Pharma (URGN) has disclosed Other Non-Current Assets for 10 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 776.23% year-over-year to $5.2 million, compared with a TTM value of $5.2 million through Dec 2025, up 776.23%, and an annual FY2025 reading of $5.2 million, up 776.23% over the prior year.
  • Other Non-Current Assets was $5.2 million for Q4 2025 at UroGen Pharma, down from $6.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $6.8 million in Q3 2025 and bottomed at $66000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $1.9 million, with a median of $1.7 million recorded in 2021.
  • The sharpest move saw Other Non-Current Assets surged 3123.64% in 2021, then tumbled 81.95% in 2024.
  • Year by year, Other Non-Current Assets stood at $1.3 million in 2021, then surged by 109.0% to $2.7 million in 2022, then fell by 25.62% to $2.0 million in 2023, then tumbled by 71.1% to $589000.0 in 2024, then surged by 776.23% to $5.2 million in 2025.
  • Business Quant data shows Other Non-Current Assets for URGN at $5.2 million in Q4 2025, $6.8 million in Q3 2025, and $801000.0 in Q2 2025.